4a1o: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:


==CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS PURH COMPLEXED WITH AICAR AND A NOVEL NUCLEOTIDE CFAIR, AT 2.48 A RESOLUTION.==
==Crystal structure of Mycobacterium tuberculosis PurH complexed with AICAR and a novel nucleotide CFAIR, at 2.48 A resolution.==
<StructureSection load='4a1o' size='340' side='right' caption='[[4a1o]], [[Resolution|resolution]] 2.48&Aring;' scene=''>
<StructureSection load='4a1o' size='340' side='right'caption='[[4a1o]], [[Resolution|resolution]] 2.48&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4a1o]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Myctu Myctu]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4A1O OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4A1O FirstGlance]. <br>
<table><tr><td colspan='2'>[[4a1o]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis_H37Rv Mycobacterium tuberculosis H37Rv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4A1O OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4A1O FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=AMZ:AMINOIMIDAZOLE+4-CARBOXAMIDE+RIBONUCLEOTIDE'>AMZ</scene>, <scene name='pdbligand=JLN:5-(FORMYLAMINO)-1-(5-O-PHOSPHONO-BETA-D-RIBOFURANOSYL)-1H-IMIDAZOLE-4-CARBOXYLIC+ACID'>JLN</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.48&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3zzm|3zzm]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=AMZ:AMINOIMIDAZOLE+4-CARBOXAMIDE+RIBONUCLEOTIDE'>AMZ</scene>, <scene name='pdbligand=JLN:5-(FORMYLAMINO)-1-(5-O-PHOSPHONO-BETA-D-RIBOFURANOSYL)-1H-IMIDAZOLE-4-CARBOXYLIC+ACID'>JLN</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4a1o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4a1o OCA], [http://pdbe.org/4a1o PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4a1o RCSB], [http://www.ebi.ac.uk/pdbsum/4a1o PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4a1o ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4a1o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4a1o OCA], [https://pdbe.org/4a1o PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4a1o RCSB], [https://www.ebi.ac.uk/pdbsum/4a1o PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4a1o ProSAT]</span></td></tr>
</table>
</table>
== Function ==
[https://www.uniprot.org/uniprot/PUR9_MYCTU PUR9_MYCTU]
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 17: Line 19:
</div>
</div>
<div class="pdbe-citations 4a1o" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 4a1o" style="background-color:#fffaf0;"></div>
==See Also==
*[[Bifunctional purine biosynthesis protein PURH|Bifunctional purine biosynthesis protein PURH]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Myctu]]
[[Category: Large Structures]]
[[Category: Baker, E N]]
[[Category: Mycobacterium tuberculosis H37Rv]]
[[Category: Bulloch, E M.M]]
[[Category: Baker EN]]
[[Category: Dickson, J M.J]]
[[Category: Bulloch EMM]]
[[Category: Greenwood, D R]]
[[Category: Dickson JMJ]]
[[Category: Middleditch, M J]]
[[Category: Greenwood DR]]
[[Category: Nours, J Le]]
[[Category: Le Nours J]]
[[Category: Zhang, Z]]
[[Category: Middleditch MJ]]
[[Category: Transferase-hydrolase]]
[[Category: Zhang Z]]

Latest revision as of 14:18, 20 December 2023

Crystal structure of Mycobacterium tuberculosis PurH complexed with AICAR and a novel nucleotide CFAIR, at 2.48 A resolution.Crystal structure of Mycobacterium tuberculosis PurH complexed with AICAR and a novel nucleotide CFAIR, at 2.48 A resolution.

Structural highlights

4a1o is a 2 chain structure with sequence from Mycobacterium tuberculosis H37Rv. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2.48Å
Ligands:, , ,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

PUR9_MYCTU

Publication Abstract from PubMed

Enzymes of the de novo purine biosynthetic pathway have been identified as essential for the growth and survival of Mycobacterium tuberculosis (Mtb), and thus have potential for the development of anti-TB drugs. The final two steps of this pathway are carried out by the bifunctional enzyme 5-aminoimidazole-4-carboxamide ribonucleotide transformylase /inosine monophosphate cyclohydrolase (ATIC), also known as PurH. This enzyme has already been the target of anti-cancer drug development. We have determined crystal structures of the Mtb ATIC (Rv0957) both with and without the substrate AICAR, at resolutions of 2.5 A and 2.2 A, respectively. As for other ATIC enzymes, the protein is folded into two domains, the N-terminal domain (residues 1-212) containing the cyclohydrolase active site and the C-terminal domain (residues 222-523) the formyl transferase active site. An adventitiously-bound nucleotide was found in the cyclohydrolase active site in both structures, and was identified by NMR and mass spectral analysis as a novel 5-formyl derivative of an earlier intermediate in the biosynthetic pathway, 4-carboxy-5-aminoimidazole ribonucleotide (CAIR). This result and other studies suggest that this novel nucleotide is a cyclohydrolase inhibitor. The dimer formed by Mtb ATIC is different from those seen for human and avian ATICs, but has a similar ~ 50 A separation of the two active sites of the bifunctional enzyme. Evidence in Mtb ATIC for half-the-sites reactivity in the cyclohydrolase domains can be attributed to ligand-induced movements that propagate across the dimer interface and may be a common feature of ATIC enzymes.

Structural analyses of a purine biosynthetic enzyme from Mycobacterium tuberculosis reveal a novel bound nucleotide.,Le Nours J, Bulloch EM, Zhang Z, Greenwood DR, Middleditch MJ, Dickson JM, Baker EN J Biol Chem. 2011 Sep 28. PMID:21956117[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Le Nours J, Bulloch EM, Zhang Z, Greenwood DR, Middleditch MJ, Dickson JM, Baker EN. Structural analyses of a purine biosynthetic enzyme from Mycobacterium tuberculosis reveal a novel bound nucleotide. J Biol Chem. 2011 Sep 28. PMID:21956117 doi:10.1074/jbc.M111.291138

4a1o, resolution 2.48Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA